RecruitingNCT01851642

Lung Disease and Its Affect on the Work of White Blood Cells in the Lungs

The Role of Conformational Diseases on Macrophage Function

Sponsor

University of Florida

Enrollment

220 participants

Start Date

Aug 9, 2007

Study Type

OBSERVATIONAL

Conditions

Alpha 1-Antitrypsin Deficiency Cystic Fibrosis (CF)AAT Deficiency AATD

Summary

The purpose of this study is to look at how Alpha-1-antitrypsin (AAT) deficiency and Cystic Fibrosis (CF) affect white blood cells in the lungs, called macrophages, and their ability to work.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Albuterol inhaler., a procedure called Blood draw., and others for people with aat deficiency, aatd, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

PROCEDUREHistory and physical exam.

At every study visit, participant's will be asked about their medical history and will have a physical exam.

PROCEDUREBlood draw.

At each study visit, participants will have an intravenous catheter (IV) placed in one of their veins and blood will be drawn from the IV for study testing.

PROCEDUREPulmonary function testing.

At every study visit, participants will have their lung function assessed. This is done by blowing forcefully at least 3 times into a tube. Testing will be done two times; before and after the use of an Albuterol inhaler.

DRUGAlbuterol inhaler.

At every study visit, participating subjects will take 2 puffs of an Albuterol inhaler after the first set of PFTs, but before the second set of PFTs. There will be at least a 30 minute period after the use of the Albuterol inhaler and the second set of PFTs.